Exploring new treatment options for refractory or relapsed acute myeloid leukemia
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
NA · Institute of Hematology & Blood Diseases Hospital, China · NCT06265545
This study is testing different treatment options for people with stubborn or returning acute myeloid leukemia to see which ones work best for them.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Sex | All |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Tianjin) |
| Trial ID | NCT06265545 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to identify the most effective therapeutic strategies for patients with refractory or relapsed acute myeloid leukemia (AML). It employs a multicenter, platform-type approach to evaluate various salvage treatment regimens, assessing overall response rates, tolerability, and survival outcomes. Patients will be screened for specific genetic mutations and assigned to different treatment arms based on their individual conditions and previous treatments. The study includes a range of interventions, including targeted therapies and chemotherapy combinations.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with refractory or relapsed acute myeloid leukemia who meet specific genetic and treatment criteria.
Not a fit: Patients with acute promyelocytic leukemia or those who have not experienced morphological recurrence of AML may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new, effective treatment options for patients with difficult-to-treat AML.
How similar studies have performed: Other studies have shown promise with targeted therapies in AML, but this specific platform approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Patients with acute myeloid leukemia (except for acute promyelocytic leukemia) diagnosed by bone marrow cell morphology, immunology and genetics above are classified according to the French-British-American Collaboration diagnostic criteria (FAB criteria) and the World Health Organization diagnostic criteria (WHO2016 criteria). 2\. Meet criteria for refractory/recurrent AML (except APL). The recurrence was morphological recurrence, excluding molecular recurrence. Except for simple extramedullary leukemia. 3\. Age and gender are not limited. 4. Informed consent must be signed before the start of the study procedure, and the informed consent must be signed by the patient himself or his immediate family if he is 18 years old and above; For young patients under the age of 18, the legal guardian shall sign the informed consent. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family. Exclusion Criteria: 1. Concurrent malignant tumors of other organs (patients requiring treatment). 2. Participants considered unsuitable for inclusion by the researchers.
Where this trial is running
Tianjin
- Blood Hospital — Tianjin, China (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: AML, Refractory, Relapsed